Accelerating Complex Biomarkers, Novel & Multimodal Endpoints to Fuel Drug-Diagnostic Innovations from Bench-to-Bedside for Global Precision Medicine Access

As regulatory headwinds turn to tailwinds, precision medicine is shifting into a new gear.

Evolving FDA approaches to LDTs and 510(k) pathways are removing long-standing friction, coordinated Rx-Dx launches are gaining pace, ctDNA and MRD are advancing as clinically meaningful endpoints, and reimbursement expansion is improving access to high-value genomic testing. At the same time, innovation in multiplex assays, multi-omics platforms, liquid biopsy, digital pathology, spatial biology, and AI-powered diagnostics, are rapidly reshaping the IVD landscape.

Fueled by $60B+ in diagnostic deal-making and strategic partnerships, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns as the industry’s esteemed end-to-end precision medicine forum. Convening 850+ senior leaders from biopharma, diagnostic, regulatory, healthcare, testing labs and multimodal communities, with expertise spanning the full value chain, gain the insights, partnerships and insider know-how to prime your team for continued clinical and commercial success.

With the race to bring scalable, accessible drug-diagnostic programs from bench-to-bedside heating up, join us in harnessing the speed, scale, and growing complexity of innovation happening in next-generation IVD platforms, multimodal data, and CDx development.